Pioneering a New Era In Asthma Control
Our Advanced Candidate: Dexpramipexole
Who We Are
A New Approach
How Did We Get Here?
Phase 3 Development Program
News Releases
Publications
Presentations
01.10.23
Areteia Therapeutics company presentationJP Morgan Healthcare Conference
Read More
02.28.22
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)
09.07.21
Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in Asthma
05.14.21
Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma
07.09.19
Dexpramipexole Responsiveness is Increased in Eosinophilic Subjects
Developing Dexpramipexole for the Treatment of Eosinophilic Disorders
